The US Department of Health and Human Services recently made a bold move. They ended a contract with Moderna. The contract was for developing an mRNA vaccine for bird flu. The reason given was that mRNA technology is not well-tested. This decision sparked a response from Pfizer's CEO, Dr. Albert Bourla. He strongly disagreed with the claim that mRNA vaccines are under-tested.

    Pfizer has administered around 1. 5 billion doses of its mRNA Covid-19 vaccine worldwide. This makes mRNA vaccines some of the most widely used in history. Bourla argues that this extensive use proves their safety and effectiveness. The HHS, however, claims that continued investment in Moderna's vaccine is not justified. They also accused the previous administration of hiding safety concerns. Bourla dismissed these claims as completely inaccurate.

    The debate comes at a time when Pfizer is making significant strides in cancer research. The company presented new data on a colorectal cancer drug at a major conference. This drug, Braftovi, showed promising results. It doubled the survival time for patients with an aggressive form of the disease. Bourla highlighted the increasing rates of colorectal cancer, especially among younger people.

    Despite the disagreement on vaccines, Bourla noted areas of agreement with the current administration. Both sides share concerns about cancer research and drug pricing policies. Bourla also expressed worries about proposed budget cuts for the National Institutes of Health. He believes these cuts could harm US leadership in biomedical sciences. This could potentially benefit other countries, like China.

    Bourla also criticized recent changes in Covid-19 vaccine policies. The FDA and CDC made updates to how vaccines are approved and recommended. Bourla thinks these changes lack scientific basis and proper procedure. He raised concerns about the feasibility of running quick clinical trials for updated vaccines.

    The CEO acknowledged the administration's willingness to engage in discussions. He mentioned maintaining a close relationship with the White House. However, he did not rule out legal action if necessary. Bourla prefers finding solutions over creating tensions. He is open to discussing the issues but will act if needed.

Pfizer's CEO Speaks Out on Vaccine Controversy

Actions